Stable transfected human p53 (mt/mt) B lymphoma Namalwa variant lines showing differential expression of the Bax-a protein were derived under hygromycin selection. Overexpression of Bax-a in these variant cells accelerates cell death induced by short or continuous treatments with various concentrations of camptothecin, etoposide, vinblastine and shows no accelerating cell death activity in cis-platinum and paclitaxel-treated cells. Activation of apoptosis and oligonucleosome-sized DNA fragmentation was observed in the variant lines with more pronounced effect in cells containing high level of Bax-a protein. These results suggest that increased cell death mediated by anticancer drugs correlates with Bax-a level of expression and that Bax-a sensitizes Namalwa cells treated at low drug concentrations. The extent of DNA synthesis inhibition following DNA topoisomerase inhibitor treatments was similar in control and all transfected Namalwa cells suggesting that Bax-a acts downstream of DNA topoisomerase-mediated DNA strand breaks. To define further the relation between Bax-a expression and apoptosis activation, kinetics of caspase activation was measured in drug-treated cells. Caspase activities were measured using specific fluorogenic peptide derivatives DABCYL-YVADAPV-EDANS and Ac-DEVD-AMC, substrates of the caspase 1-like and caspase 3-like families, respectively. In control and Bax-a transfected Namalwa cells no increase in caspase 1-like activity was detected following camptothecin and etoposide treatments. In contrast, a significant difference in Ac-DEVD-AMC hydrolysis activity was observed in Bax-a transfected Namalwa cells compared to that of control Namalwa cells after camptothecin and etoposide treatment. Increased caspase 3-like activity correlated also with poly(ADPribosyl) polymerase cleavage. Taken together, these results suggest that Bax-a sensitize B lymphoma cells to series of anticancer drugs and accelerates the activation of apoptotic protease cascade.
Introduction
Programmed cell death (apoptosis) is a fundamental process essential for normal regulation of cell homeostasis and seems to play an important role in tumor development and progression (Raff et al, 1994; Thompson, 1995; Wyllie, 1997) . All of the anticancer drugs used in clinic can induce apoptosis in various cell lines but the mechanisms by which these drugs activate programmed cell death are just beginning to be examined (Hickman, 1996; Reed, 1995) . Several studies have provided major evidence that specific genes can act either as inhibitor or activator in the apoptotic process. The human Ced-9/Bcl-like family includes a series of related gene products that either inhibits apoptosis such as Bcl-2 (Hockenbery et al, 1990; Korsmeyer, 1992; Reed, 1997; Vaux et al, 1988) , Bcl-xL (Boise et al, 1993) , Mcl-1 (Kozopas et al, 1993) , A1 (Lin et al, 1993) , Bag (Takayama et al, 1995 (Takayama et al, , 1996 , Bfl-1 (Choi et al, 1995) , Bcl-w (Gibson et al, 1996) and Brag-1 (Das et al, 1996) , while others such as Bax (Oltvai et al, 1993) , Bcl-xS (Boise et al, 1993) , Bak Farrow et al, 1995; Kiefer et al, 1995) , Bad , Bik (Boyd et al, 1995) , and Bid are associated with the activation of apoptosis. Bcl-2 has been found translocated [t(14 : 18) ] in human B cell lymphoma and is thought to contribute to the development of B-cell neoplasia (Clarke et al, 1986; Tsujiimoto et al, 1984) , while bcl-xL is found often highly expressed in B lymphoma tumor cells (Xerri et al, 1996) . Bcl-2 and Bcl-xL are also associated with cell death protection after treatment with anticancer compounds (Datta et al, 1995; Dole et al, 1995; Fang et al, 1995; Hockenbery, 1995; Ibrado et al, 1996; Korsmeyer, 1995; Reed, 1995) and recent observations suggested that Bax-a (Chresta et al, 1996; Krajewski et al, 1995; Sakakura et al, 1996; Thomas et al, 1996; Wagener et al, 1996) and Bcl-xS (Ealovega et al, 1996; Sumantran et al, 1995) may inhibit protective effects conferred by Bcl-2 and Bcl-xL and accelerate cell death induced by some anticancer drugs.
An emerging family of Ced-3/Ice-like cysteine proteases (caspases) has been also identified and several studies have revealed their importance in executing the process of cell death itself. The caspases are separated in three subfamilies based on their degrees of homology and by phylogenetic analysis; the ICE-related family includes Ice/ caspase-1 itself with its spliced isoforms Yuan, 1993) , Tx/Ich-2/Ice rel-II/caspase-4 (Faucheu et al, 1995; Kamens et al, 1995; Munday et al, 1995) , Ty/ Ice rel-III/caspase-5 (Faucheu et al, 1996; Munday et al, 1995) and Ich-3/caspase-11 ; the CPP32-related family includes CPP32/Yama/Apopain/caspase-3 (Fernandes- Alnemri et al, 1994; Nicholson et al, 1995; Tewari et al, 1995) , Mch-2/caspase-6 (Fernandes- Alnemri et al, 1995) , Mch-3/Ice-Lap3/Cmh-1/caspase-7 (Duan et al, 1996a; Lippke et al, 1996) , Mch-4/caspase-10 (FernandesAlnemri et al, 1996) , Mch-5/Flice/Mach/caspase-8 (Boldin et al, 1996; Fernandes-Alnemri et al, 1996; Muzio et al, 1996) and the third group includes Ich-1[and s]/caspase-2 and Ice-Lap6/Mch6/caspase-9 (Duan et al, 1996b) .
Chemotherapeutic drugs such as DNA topoisomerase I (top 1) and II (top 2) inhibitors (camptothecin, CPT; etoposide, VP16, respectively) trigger apoptosis in various cell lines (Barry et al, 1990; Bertrand et al, 1991 Bertrand et al, , 1993 Del Bino et al, 1992; Jaxel et al, 1988; Kaufmann, 1989; Solary et al, 1993; Walker et al, 1991) . These drugs are known to stabilize a transient intermediate of topoisomerase reactions where enzymes are linked to the 3' (top 1) or 5' (top 2) terminus of a DNA duplex producing DNA single-or double-strand breaks (Gupta et al, 1995; Pommier, 1997) . The unknown signals emerging from DNA damage induced by chemotherapy drugs like DNA topoisomerase inhibitors are influenced by a series of checkpoints and are related to specific gene expression. Although it has been proposed that Bax-a is a wild-type p53 response gene, DNA topoisomerase inhibitors are able to trigger apoptosis in p53 mutated and null cells. Thus, to analyze further the relation between Bax-a expression, drug sensitivity and caspase activation, we have developed human B lymphoma Namalwa variant lines that express differential levels of Bax-a protein.
In this paper we show that Bax-a accelerates apoptosis induced by CPT (DNA topoisomerase I inhibitor), VP16 (DNA topoisomerase II inhibitor) and vinblastine (a tubulin polymerization inhibitor) even at very low drug concentration. The promoting cell death activity of Bax-a correlates also with its level of expression. Bax-a does not interfere with primary mechanism of action of DNA topoisomerase inhibitor CPT and acts downstream of DNA damagemediated DNA synthesis inhibition. However, Bax-a acts upstream of caspase and DNA fragmentation induction and accelerates the activation of caspase 3-like at low drug concentration. Taken together, these results suggest that Bax-a acts primarily downstream of the primary effect of chemotherapy drugs such as CPT and sensitizes B lymphoma cells to a series of anticancer drugs. Bax-a functions also upstream of caspase 3-like in the apoptotic process and accelerates their activation.
Results

Expression of Bax-a and Bcl-xL in Namalwa cell lines
The human B lymphoma Namalwa cells are p53 double mutant cells (O'Connor et al, 1993 ) that contain two copies of the Epstein ± Barr virus (EBV) genome integrated in opposite orientations on chromosome 1 (Lawrence et al, 1988) . The Namalwa cells are characterized by their absence of EBV episomes and the lack of virus replication in response to inducers (Klein and Dombos, 1973; Matsuo et al, 1984) . These cells express nuclear antigen proteins belonging to the EBNA-3 family, which expression was proposed to play a role to maintain the lymphoblastoid cells in an immortalized state (Luka et al, 1978; Sawada et al, 1989 ) although a causal role for EBV in tumor development remains obscure (Horner et al, 1995) . However, these cells do not express the latent membrane proteins of the LMP family (Sample et al, 1989) and the Bcl-2 homolog protein BHFR1, which expression is primarily linked with virus replication and lytic induction (Pearson et al, 1987) and more often associated with nasopharyngeal carcinoma (Horner et al, 1995) . Moreover, these cells show high molecular weight and oligonucleosomesized DNA fragmentation patterns typical of apoptosis after short DNA damaging agent treatments (Sane et al, 1997) and express members of the Ced-9/Bcl-like family, such as Bcl-2, Bax-a and Bcl-xL (Figure 1, lower panels) . To analyze the effect of Bax-a expression on drug response and caspase activation in human B lymphoma cells, we have developed Namalwa variant lines that express differential levels of Bax-a protein. A Namalwa variant line that overexpress Bcl-xL was also derived to compare their effects. The human Bax-a and Bcl-xL cDNAs were first amplified by RT ± PCR and inserted in a modified pCEP4 vector containing Kosak and hemagglutinin epitope tag sequences (HA-tag). After transfection, Namalwa cells were selected as bulk culture under hygromycin (500 mg/ ml, 1.5 mg/ml) and selection were maintained for about 2 months to obtain stable lines prior to perform the experiments. Control Namalwa cells did not survive under hygromycin selection. Western blot analysis indicates that the HA-Bax-a protein is expressed at different levels with respect to hygromycin concentration (Figure 1, upper left panel) . The highest expression of HA-Bax-a has been found in transfected cells selected at 1.5 mg/ml hygromycin. High level of expression of HA-Bcl-xL was also achieved in cells selected at 1.5 mg/ml hygromycin (Figure 1 , upper right panel). Protein expression was also visualized by immunohistochemical staining and micrographs show that all cells express the HA-epitope tagged Bax-a and Bcl-xL proteins (Figure 2 ).
Effect of Bax-a upon apoptosis and DNA fragmentation
To test Bax-a activity in the selected transfected cell lines, we first determined HA-Bax-a potency to promote cell death in cells grown in low serum concentration (0.1%) or triggered with an anti-CD95/Fas antibodies for 24 h (Figure 3) . We routinely used a filter DNA binding assay to monitor and quantitate kinetics of DNA fragmentation in cells undergoing apoptosis (Bertrand et al, 1991 . Higher expression of Bax-a in Namalwa cells increases rates of DNA fragmentation both in cells grown in low serum concentration (0.1%) and in the presence of anti-CD95/Fas antibodies for 24 h (Figure 3 ). The amount of DNA fragmentation has been found higher in cells expressing the highest level of Bax-a protein.
To analyze the effect of Bax-a upon anticancer druginduced apoptosis we first evaluated the effect of CPT, a DNA topoisomerase I inhibitor, in control and Bax-a transfected Namalwa variant lines. Several studies have shown that CPT, a DNA topoisomerase I inhibitor, activates the morphological changes and internucleosomal DNA fragmentation associated with apoptosis. Short treatments (30 min) with CPT at moderate concentrations (0.1 mM ± 0.5 mM) induced apoptosis in control Namalwa cells while low concentration of CPT such as 0.01 mM does not trigger apoptosis significantly (Figure 4) . However in the Bax-a transfected Namalwa cells, both the kinetic and extent of DNA fragmentation were more pronounced after CPT treatment at low concentration ( Figure 4) . Moreover, the promoting cell death activity of Bax-a after such treatment was more pronounced in cells selected at 1.5 mg/ml hygromycin, expressing the highest level of Bax-a. At 0.01 mM and 0.05 mM CPT, the promoting cell death effect of Bax-a in the transfected lines was relatively more pronounced compared to the effect of CPT in control Namalwa cells. At higher CPT concentration (0.1 mM and 0.5 mM) the difference between the CPT-treated control and Bax-a transfected Namalwa cell line selected at 1.5 mg/ml hygromycin seems to be less pronounced ( Figure 4 ) and no significant differences were detected in the Bax-a variant line selected at 0.5 mg/ml hygromycin when compared to Namalwa cells (data not shown). These results indicate a direct relation between the amount of Bax-a and the degree of apoptosis induced by low concentration CPT. Thus, higher level of Bax-a sensitizes these cells to low drug concentration. For comparison, Namalwa cells transfected with HA-Bcl-xL and selected at 1.5 mg/ml hygromycin, are completely resistant to CPT-induced apoptosis ( Figure 4 ; open circles).
CPT traps and stabilizes an intermediate of DNA topoisomerase I reaction when the enzyme is covalently linked to DNA. Stabilization of these cleavable complexes induces DNA strand breaks. These enzyme-linked DNA adducts on active replication forks inhibit DNA synthesis. DNA replication inhibition is one of the most widely explored processes to be implicated in the cytotoxic mechanism of action of DNA topoisomerase I inhibitors (Gupta et al, 1995) . To determine whether Bax-a acts primarily upstream or downstream of CPT translated effect on DNA synthesis, rates of DNA synthesis were measured by thymidine pulse incorporation immediately after CPT treatments. Table 1 shows that in Namalwa control cells, immediately following CPT treatment at 0.01 mM, 0.05 mM, 0.1 mM and 0.5 mM, DNA synthesis rates were reduced to approximately 85, 75, 65 and 59% to that of control untreated cells, respectively. The extent of DNA synthesis reduction was similar in the two transfected Namalwa cells treated with the same concentrations of CPT with rates of DNA synthesis of approximately 80, 72, 64 and 57% to that of Bax-a transfected untreated cells, respectively. These results suggest that Bax-a does not interfere with the primary mechanism of action of CPT and does not amplify CPT-induced DNA synthesis inhibition.
Modulation of cell death by Bax-a was also observed in cells treated with VP-16 (DNA topoisomerase II inhibitor) and vinblastine (tubulin polymerization inhibitor). The promoting death activity of Bax-a was more pronounced in the variant line expressing the highest level of Bax-a ( Figure 5 ) at low VP-16 and vinblastine concentrations. While the control Namalwa cells do not show significant DNA fragmentation when treated at or below 20 mM VP-16 and vinblastine, in the high Bax-a expressing cells more Cytosolic extracts were prepared as described in Materials and Methods from control, HA-Bax-a transfected Namalwa cells selected at 0.50 mg/ml and 1.5 mg/ml hygromycin (left panel) and HA-Bcl-xL transfected cells selected at 1.5 mg/ml hygromycin (right panel). Following SDS-polyacrylamide gel electrophoresis and electrophoretic transfer, HA-Bax-a and HA-Bcl-xL proteins were detected using anti-HA peptide monoclonal antibodies. Visualization of signals was performed by ECL and autoradiography (lower panels). Cytosolic extracts were prepared from control Namalwa cells. Following SDS-polyacrylamide gel electrophoresis and electrophoretic transfer, Bcl-2, Bax-a and Bcl-xL proteins were detected using specific antibodies. Visualization of signals was performed by ECL and autoradiography than 70% DNA fragmentation was detected 8 h after drug treatment ( Figure 5 ). As with CPT, these results show that higher level of Bax-a sensitizes these cells to low VP-16 and vinblastine concentrations. Conversely, overexpression of Bax-a did not significantly sensitize these cells to paclitaxel and cis-platinum(II) diammine dichloride treatment neither 8 h nor 24 h after drug treatment ( Figure 5 ). To confirm the specificity of the DNA fragmentation observed by the filter assay, we visualized the intensity of the oligonucleosome-sized DNA fragments caused by these drugs in Namalwa and Namalwa-Bax cells ( Figure  6 ). Overexpression of Bcl-xL in these cells completely abrogates the occurrence of DNA fragmentation ( Figure 6 ).
Effect of Bax-a on caspase activation
A series of caspases are involved in the apoptotic process (Kumar and Lavin, 1996; Patel et al, 1996) . To determine whether Bax-a accelerates caspase activation, we monitored caspase 1-like and caspase 3-like activities using specific fluorogenic peptide substrates. In cytosolic extracts obtained from Namalwa cells, a slow increase in caspase 3-like activity was detected after 0.05 mM CPT or 10 mM VP16 treatment ( Figure 7 ). The kinetic of caspase 3-like activity correlates with the slow activation of DNA fragmentation following CPT and VP-16 treatment in control Namalwa cells (Figures 4 and 5) . In contrast, in Bax-a transfected Namalwa cells a rapid increase in caspase 3-like activity was detected following CPT and VP-16 treatment (Figure 7 ). These results suggest that caspase 3-like activity correlates with occurrence of DNA fragmentation and that Bax-a accelerates caspase 3-like activation. No increase in DABCYL-YVADAPV-EDANS hydrolysis was detected following CPT and VP-16 treatment in both cell lines suggesting that caspase 1-like activity be neither activated nor involved in the apoptotic process induced by CPT and VP-16 in these cells. Moreover, caspase 3 activation was not detected in cells overexpressing the HA-Bcl-xL protein after CPT and VP-16 treatment (data not shown).
These observations are consistent with the protective effect conferred by Bcl-xL in these cells. To validate these findings, kinetic of poly(ADPribosyl) polymerase (PARP) cleavage, a known substrate of caspase 3-like activity (Lazebnik et al, 1994) , was monitored in control and Bax-a transfected Namalwa cells
Namalwa control
Namalwa Bax-α Namalwa control Namalwa Bcl-xL Figure 2 Immunohistochemical revelation of the HA-Bax-a and HA-Bcl-xL proteins in transfected Namalwa variant cells. Upper panels are control Namalwa (left) and HA-Bax-a transfected Namalwa cells (right). Lower panels are control Namalwa (left) and HA-Bcl-xL transfected Namalwa cells (right) treated with VP-16. Figure 8 shows that PARP cleavage and the appearance of the small 24 kDa fragment occurs much more extensively in VP-16-treated Bax-a transfected Namalwa cells compared to that of VP-16-treated control Namalwa cells. Taken together, our results suggest that Bax-a accelerate the processing and activation of caspase 3-like at low drug concentrations.
Discussion
The human Bax gene belongs to the Ced-9/Bcl-like familiy that regulates cell survival and cell death. Several mRNA isoforms have been isolated and derived likely from alternative splicing of a single Bax gene mapped to human chromosome 19q13.3-q13.4 (Apte et al, 1995; Oltvai et al, 1993) . The first study with Bax gene product indicated that Bax-a has a cell death promoting activity, inhibiting the protective effect conferred by Bcl-2 in an interleukine (IL)-3 dependent cell line upon cytokine removal (Oltvai et al, 1993) . Immunohistochemical analysis of Bax expression in mice showed that Bax proteins are expressed in a wide variety of cell types and predominantly in a variety of epithelial cells, in the thymic medulla and in the germinal center lymphocytes of lymph nodes and in several population of reproductive and neuronal cells . Yeast two-hybrid assays indicated that Bax-a interacts and heterodimerizes with itself, Bcl-2, Bcl-xL, Mcl-1 and A-1 (Sedlak et al, 1995) . Bax-deficient mice displayed thymocytes and B cells hyperplasia and disordered ovaries granulosa cells, atypical male germ cells and no mature haploid sperm (Knudson et al, H-thymidine labeled incorporation were determined by 10 min pulse experiments. Values are expressed as % of DNA synthesis relative to control untreated cells and represent the means+S.E. of two independent experiments performed in triplicate (n=6). Nam -bax 0.50 and Nam-bax 1.50 mean Namalwa cells transfected with Bax and selected at 0.50 mg/ml and 1.5 mg/ml hygromycin, respectively 1995). Thus, low Bax expression may result in hyperplasia and plays a role in tumor development.
In this study, by selecting transfected B-lymphoma Namalwa variant cells that express differential level of Bax-a, we show that its effect is directly related to its level of expression. Reduced expression of Bax was associated recently with poor response rates to chemotherapy in women with metastatic breast adenocarcinoma (Bargou et al, 1995) . Gene transfer studies in human breast cell lines showed that Bax-a sensitized these cells to radiation-and drug-induced apoptosis (Sakakura et al, 1997; Wagener et al, 1996) . Other studies have indicated that the Bax : Bcl-2 ratio in human testicular tumors and B-cell chronic lymphocytic leukemia is related to cell susceptibility to undergo apoptosis (Chresta et al, 1996; McConkey et al, 1996; Thomas et al, 1996) . Ordered balance within the ratio of effector and repressor proteins regulating the decision of a cell to survive or die has already been suggested to form an important checkpoint for cell death (Oltvai and Korsmeyer, 1994) . Our results are consistent with that model and indicate that the level of expression of Bax-a might be an important control point regulating anticancer drug sensitivity in tumor cells. Others have reported also that Bax-a can antagonize the protective effects of Bcl-xL during VP-16-induced apoptosis in FL5.12 cells and interestingly in these cells, Bax-a was also much less potent to promote cell death induced by cisplatinum consistent with our observations in Namalwa cells (Simonian et al, 1996) . Although our observations suggest that Bax-a does not promote paclitaxel-induced apoptosis in the B lymphoma Namalwa cells, others have reported that a mean of tenfold increased level of murine Bax expression in human SW626 ovarian cancer cells promotes cell death induced by paclitaxel (Strobel et al, 1996) . No rationale explanation could be provided to explain the different observations, but the difference in paclitaxel sensitivity between these cell lines may reflect the presence or absence of other unknown factors that are involved in paclitaxel-induced apoptosis.
Our results indicate that Bax-a does not interfere with the primary mechanism of action of anticancer drugs such as CPT, since extent of DNA synthesis reduction is found similar in all Bax-a transfected and control cells following CPT treatment. Although signals emerging from unfinished replication and damaged DNA are not yet fully understood, this study and others, indicate that Bax-a is a control point and influences the decision of a cell to undergo apoptosis. It has been proposed that Bax-a is a wild-type p53 primary response gene, in p53-regulated pathway for apoptosis activation Miyashita and Reed, 1995) . The Namalwa cells are p53 double mutant cells (codon 248/exon 7; Arg to Gln/Arg to Trp) (O'Connor et al, 1993) and it is unlikely that mutated p53 plays a role in the induction of apoptosis in these lines. Nevertheless, gene transfer-mediated elevation of Bax-a sensitizes these cells to some but not all anticancer agents in a p53-independent manner. Moreover, the expression of EBNA-3 protein family in the Namalwa cells are unlikely to play a role in apoptosis regulation (Horner et al, 1995) .
Activation of apoptotic proteases are known to be a critical step in dying cells. Series of caspases were reported to play a central role in executing apoptosis. In this study, we investigate the relation between Bax-a and the activation of caspases. We examined whether Bax-a accelerates the activation of the proteases required in the execution phase of apoptosis. Our experiments using fluorogenic substrates provide evidence that in cells undergoing apoptosis induced by CPT and VP-16, the activation of caspase-3 like was accelerated in Bax-a transfected cells. No evidence of caspase 1-like activation was detected in these cells treated with CPT and VP-16. Caspase 3-like activation was also associated with PARP cleavage, a known substrate for these proteases (Lazebnik et al, 1994) . Interestingly, the effect of Bax-a on caspase activation is opposite to that of Bcl-2 and Bcl-xL. Recent studies have reported that Bcl-2 like Bcl-xL prevents the activation of caspases in cultured cells (Monney et al, 1996; Shimizu et al, 1996) . Activation of caspase 3 in Baxinduced cell death was reported recently in several studies (Deveraux et al, 1997; Kitanaka et al, 1997; Xiang et al, 1996) . Interestingly, blocking caspase 3-like activities by the protease inhibitor N-benzyloxycabonyl-Val-Ala-Aspfluoromethylketone prevents the cleavage of nuclear and cytosolic substrates and DNA fragmentation but does not prevent cells to die by a necrosis-like mode of cell death (Hirsch et al, 1997; Xiang et al, 1996) .
In summary, our results indicate that Bax-a is a primary controlpoint that promotes transmission of cell death signals emerging from DNA damage in a p53-independent manner and accelerates activation of an apoptotic protease cascade. The identification of cell death signals triggered by DNA damage in p53 mutant cells and understanding how Bax-a promotes caspase activation and DNA fragmentation, will certainly help to design in future new therapeutic strategies to circumvent drug resistance mechanisms in p53-independent pathway of apoptosis. Cell culture and DNA labeling
Materials and Methods
Chemicals
The human Namalwa cell line obtained from the American Type Culture Collection (Rockville, MD), were grown in suspension culture at 378C in the presence of 5% CO2 in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell culture products were purchased from Gibco BRL Life Technologies (Grand Island, NY). For DNA labeling, Namalwa cells were grown with [ 14 -C]thymidine (0.02 mCi/ml) for 24 h and then chased in isotope-free medium overnight prior to drug treatment.
cDNA cloning and transfection
The human Bax-a and Bcl-xL cDNAs were cloned by RT ± PCR from total RNA using specific adapter primers containing NotI sequences at the ATG start codon and TAA stop codon. The amplified fragments were first cloned in pCRII vector (TA cloning system; Invitrogen, San Diego, CA) and then subcloned at the NotI restriction site in the eucaryotic expression vector pCEP4 (InVitrogen) that has been modified to include consensus Kosak and hemagglutinin epitope Tag sequences (HA-Tag) between the BamHI and NotI restriction sites. Vectors were sequenced by ALF DNA sequencer (LKB-Pharmacia Biotech, Upsalla, Sweden) using both vector and internal primers. Purified pCEP4-HA-Bax, pCEP4-HA-Bcl-xL constructs and pCEP4-mock vector were transfected in Namalwa cells by electroporation at 0.27 kVolts (Gene Pulser, BioRad, Hercules, CA). Transfected cells were grown under hygromycin selection for 2 ± 3 months to obtain stable lines prior to perform the experiments. Control Namalwa cells do not survive under hygromycin selection. Drug sensitivity of control and pCEP4-mock transfected variant lines were identical. Restriction and modification enzymes were purchased either from Pharmacia or Gibco BRL.
Western blot and immunohistochemistry analysis
For Western blot, control and transfected Namalwa cells were collected by centrifugation, washed twice with ice-cold phosphatebuffered saline (PBS) and then homogenized in a lysis buffer containing 5 mM HEPES pH 7.4, 160 mM KCl, 40 mM NaCl, 10 mM MgCl 2 , 1 mM PMSF, 0.5% NP40 and a cocktail of protease inhibitors (Complete TM , Boehringer-Mannheim) at 48C for 30 min with agitation. After centrifugation, supernatants were collected as cytosolic protein extracts. Protein concentrations were determined using the Bradford assay with bovine serum albumin as standard. Antibodies to the peptide epitope derived from the hemagglutinin protein of human influenza virus (HA epitope tag) and to human PARP protein were obtained from Boehringer-Mannheim. Affinity purified antibodies to human Bcl-2 and Bax were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA) and antibodies to Bcl-xL were obained from CalBiochem (San Diego, CA). Enhanced cheminulescence detection of peroxidase-labeled secondary antibodies was performed using Amersham Life Science reagents. Expression of HA -Bax and -Bcl-xL by immunohistochemistry was visualized using anti-HA mouse monoclonal antibodies (Boehringer-Mannheim) as primary antibody (10 mg/ml), a biotinylated goat anti-mouse (Sigma) as secondary antibody (10 mg/ml) followed by a streptavidin-alcaline phosphatase complex (Sigma) and colorimetric reaction using FastRed TR/ Naphthol AS-MX (Sigma). Briefly, cells were spread by centrifugation on microscope slides and fixed in a solution containing 50% acetone and 50% methanol. Permeable cells were then incubated for 30 min in PBS buffered solution containing 10% (v/v) goat serum and 5% (w/v) bovine serum albumin (Sol A). Cells were then incubated with the primary antibody diluted in Sol A for 30 min, followed by several washings with Sol A and then incubated with the secondary antibodies diluted in Sol A. After several washes in Sol A, cells were incubated with a streptavidin-alcaline complex, washed again and incubated with a solution of FastRed TR/Naphthol As-MX according to the manufacturer's instructions (Sigma). Cells were then analyzed under an Axioscop camera-and equipped microscope (Carl Zeiss, West Germany).
DNA ®lter elution assay
DNA filter elution assays were designed to monitor and quantitate DNA fragmentation associated with apoptosis . Each sample (approximately 0.5610 6 14 C-thymidine-labeled cells) is loaded onto a protein-adsorbing filter (vinyl/acrylic copolymers filters, Metricel membrane, 0.8 mm pore size, 25 mm diameter, Gelman Sciences Inc., Ann Arbor, MI) mounted in a Millipore filter holder connected to a 50 ml syringe. Cells are then washed with 5 ml of phosphate buffered saline (PBS). As soon as the washing solution has dripped through by gravity, lysis is performed with 5 ml of lysis solution (0.2% sodium sarkosyl ± 2 M Nacl ± 0.04 M EDTA, pH 10.0). After the lysis has dripped through by gravity, it is washed from the filters with 5 ml of 0.02 M EDTA (pH 10.0). The filter is then processed as described . Briefly, it was placed in a scintillation vial to which 1.0 ml of 1 N HCl is added. The vial is sealed and heated for 1 h at 608C to depurinate the DNA. Then, 2.5 ml of 0.4 N NaOH is added and allowed to stand 1 h at room temperature to release the labeled DNA from the filters. Radioactivity was counted by liquid scintillation spectrometry in each fraction (loading wash, lysis, EDTA wash, filter). DNA fragmentation was determined as the fraction of DNA in the loading wash fraction+lysis fraction+EDTA wash fraction relative to total DNA (loading wash+lysis+EDTA wash+filter). Results are expressed as the percentage of DNA fragmented in treated cells compared to DNA fragmented in control untreated cells (background) using the formula:
where F and F0 represent DNA fragmentation in treated and control cells, respectively.
Analysis of DNA fragmentation by agarose gel electrophoresis
To visualize the oligonucleosome-sized DNA fragments, at specified times after drug treatment cellular DNA was extracted by a salting-out procedure as described previously (Miller et al, 1988) . Electrophoresis was done in 1.6% agarose gel in Tris-acetate buffer (pH 8.0). Following electrophoresis DNA was visualized by ethidium bromide staining.
Measurement of thymidine incorporation
Control and transfected Namalwa cells were prelabeled with 14 C-thymidine (0.02 mCi/ml) for 24 h and then chased in isotope-free medium overnight prior to drug treatment. Cells were incubated in CPT containing medium for 30 min. After drug treatment, cells were washed twice with complete medium and rates of nucleotide incorporation were measured by 10 min pulse experiments with [ 3 H]thymidine (10 mCi/ml) as described (Bertrand et al, 1992) . Nucleotide incorporation was stopped by adding 10 ml of ice-cold PBS and cells were quickly pelleted by centrifugation (1000 g, 3 min, 48C). Acidinsoluble nucleotides were precipitated on ice with 10% trichloracetic acid. The precipitates were dissolved in 0.4 N NaOH and radioactivity was monitored by scintillation spectrometry. (Bertrand et al, 1992) .
Caspase activity determination
Cytosolic extracts are prepared by washing control and transfected Namalwa cells twice by centrifugation/resuspension in 10 ml ice-cold PBS (without Ca 2+ and Mg 2+ ). Cells are then homogenized at 48C for 30 min in a lysis buffer containing 100 mM HEPES (pH 7.5), 5 mM EDTA, 5 mM DTT, 20% glycerol and 0.5% NP-40. Samples are then centrifuged (13 000 g for 10 min at 48C) and supernatants collected as cytosolic extracts. Caspase activities were measured by monitoring fluorescence continuously in a dual luminescence fluoremeter (LS 50B Perkin Elmer) using excitation wavelength of 360 nm and emission wavelength of 490 nm for the substrate DABCYL-YVADAPV-EDANS and excitation wavelength of 380 nm and emission wavelength of 460 nm for the substrate Ac-DEVD-AMC. Reactions were carried out in cuvettes and temperature maintained at 378C using a waterjacketed sample compartment. The assay mixture contained 100 mM HEPES (pH 7.5), 20% (v/v) glycerol, 5 mM DTT, 5 mM EDTA and 200 mM fluorogenic peptides. Enzyme activities were determined as initial velocities and expressed as relative intensity/min/mg.
